ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO217

Peritoneal Dialysis Mineral Metabolism Disorders: Results from the BRAZPDII

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Truyts, Cesar Augusto madid, Universidade de São Paulo, São Paulo, Brazil
  • Nunes, Lucas Acatauassu, Universidade de São Paulo, São Paulo, Brazil
  • Custodio, Melani, Universidade de São Paulo, São Paulo, Brazil
  • Moyses, Rosa M.A., Universidade Nove de Julho, São Paulo, Brazil
  • Pecoits-Filho, Roberto, Pontificia Universidade Catolica do Parana, Curitiba, Paraná, Brazil
  • Jorgetti, Vanda, Universidade de São Paulo, São Paulo, Brazil
  • Moraes, Thyago Proença de, Pontificia Universidade Catolica do Parana, Curitiba, Paraná, Brazil
Background

Few studies evaluate mineral and bone disorders (MBD) in patients treated with peritoneal dialysis (PD), and the main guideline guiding their treatment were based on studies performed in patients treated with hemodialysis. BRAZPDII is a cohort of patients from 114 dialysis centers in Brazil, which contains data from 9.905 patients on peritoneal dialysis. We analyzed biochemical markers related to MBD (calcium (Ca), phosphorus (P) and parathormone (PTH)), categorized patients in accordance with the targets proposed guideline Kidney Disease: Improving Global Outcomes (KDIGO),and compared the survival index between the groups which maintained the biochemical markers within or without the normal ranges

Methods

We recruited 844 patients from BRAZPDII, who had MBD biomarker data, and followed them up for 24 months. Cox proporcional was used to eliminate potencial variable confounders, and Kaplan-Meier estimator was used to compare the survival rate between the groups.

Results

Patients with Ca and P within the normal range using KDIGO definitions (8.4-10.2mg/dL and 3.5-5.5mg/dL, respectively) were associated with lower mortality (p<0.05; HR 1.63 and 1.79, respectively). PTH levels were not associated with mortality, regardless of the ranges proposed by KDIGO guideline (150-600).

Conclusion

Keeping calcium and phosphate within the range as suggested by KDIGO was associated with lower mortality in PD patients. PTH levels were not associated with mortality risks.

Relative risk of mortality and biochemical parameters out of range (KDIGO)
Biochemical parameterHR95% CIp-value
Calcium1.631.12-2.380.01
Phosphate1.791.26-2.540.001
PTH0.990.99-1.000.56

Funding

  • Commercial Support